Genavia Therapeutics Licenses Technology from Origen Therapeutics, Inc. for Cost-Efficient Production of Human Therapeutics in Chicken Eggs
3/9/2009 9:31:57 AM
More...
|
Symphogen A/S And Origen Therapeutics, Inc. Collaborate to Produce Transgenic Chicken for Generation of Fully Human Antibody Therapeutics
3/6/2009 10:12:59 AM
More...
|
Origen Therapeutics, Inc. Announces Change In Chief Financial Officer And Reports Naked Short Selling To SEC
10/6/2008 11:19:56 AM
More...
|
Origen Therapeutics, Inc. Appoints Phil Leighton as Director of Research and Announces Departure of Robert Etches, VP of Research
6/23/2008 8:50:37 AM
More...
|
Origen Therapeutics, Inc. Receives $2 Million ATP Grant to Advance Technology for Discovery and Production of Human Polyclonal Antibodies from Transgenic Chickens
10/3/2007 10:16:19 AM
More...
|
Chickens Genetically Altered To Pass On Inserted Trait
6/8/2006 1:29:28 PM
More...
|
Origen Therapeutics, Inc. Publishes In Nature A Robust And Versatile Method For Creating Transgenic Chickens
6/8/2006 12:47:47 PM
More...
|
New Chicken Gene-Transfer System Holds Promise For Research And Industry
6/7/2006 1:21:09 PM
More...
|
Origen Therapeutics, Inc. Receives SBIR Grant Aimed At Furthering Human Polyclonal Antibody Development In Chickens; Over $5 Million
10/19/2005 5:10:02 PM
More...
|
First Production Of Human Monoclonal Antibodies In Chicken Eggs Published In Nature Biotechnology
10/19/2005 5:09:11 PM
More...
|